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Letters to the Editor
Ischemia-Modified Albumin
and Myocardial Ischemia
Sbarouni et al. (1) reported on “Ischemia-Modified Albumin
[IMA] in Relation to Exercise Stress Testing [EST]” in a previous
issue of the Journal. Although the investigators found significant
differences in the IMA values at baseline, peak exercise, and after
EST, there was no relation between the IMA changes and the
result of the EST. The researchers stated that changes in IMA
levels do not reflect myocardial ischemia and that IMA does not
seem to improve the accuracy of EST. Although these are highly
interesting results, some important points must be considered in
this study.
Previous studies have shown that IMA is a marker of myocar-
dial ischemia, and it was accepted that IMA is an early marker to
help in ruling out patients with acute coronary syndrome (2,3).
Interestingly, Sbarouni et al. (1) concluded that IMA levels do not
indicate myocardial ischemia different from these other studies.
False negative and false positive results of exercise testing are
important clinical problems in diagnosis of coronary artery disease
(CAD). The sensitivity and specificity of EST range between 60%
and 70% (4,5). Approximately 30% to 40% more false negative
results may be obtained in clinical practice. Therefore, each
positive EST is not accepted as a sign of myocardial ischemia.
However, in the study by Sbarouni et al. (1), a positive stress test
is accepted as indicative of myocardial ischemia. It is not men-
tioned how many patients with positive EST have myocardial
ischemia. In our opinion, lack of this important information may
change the study results.
Other conflicts and controversial subjects are related to results
from postexercise IMA levels. Because plasma IMA levels increase
within minutes after myocardial ischemia, peak exercise IMA
levels may not indicate myocardial ischemia. However, postexer-
cise IMA levels may be helpful to determine myocardial ischemia
during exercise. Previously, it was demonstrated that IMA levels
decrease after physical exercise, and it was hypothesized that this
immediate decrease may have been attributable to interference in
the IMA measurement by lactate produced during skeletal muscle
ischemia (6,7) However, release of lactate after EST in patients
with peripheral vascular disease has been reported (8) Although
Sbarouni et al. (1) concluded that a decrease in IMA levels is
associated with hemoconcentration, it was unknown whether
peripheral vascular disease was present in the study population.
Therefore, possible peripheral vascular disease in patients may
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Ischemia-Modified Albumin:
The Importance of Oxidative Stress
We read with interest the recent study by Sbarouni et al. (1) which
adds to the growing body of evidence regarding ischemia-modified
albumin (IMA). Interestingly, in their study, the IMA levels
dropped significantly at peak exercise in both patients with positive
and negative exercise stress-test responses, suggesting that the
observed changes in IMA levels may not reflect myocardial
ischemia. In addition to Sbarouni et al. (1), other investigators
have previously shown reduced IMA levels immediately after
exercise in different clinical conditions: for example, exercise-
induced skeletal muscle ischemia in patients with peripheral
vascular disease (2) and induced forearm ischemia in normal
volunteers (3). The possible explanations for the observed IMA
changes after exertion include an increase in albumin levels due to
hemoconcentration and the resultant decrease in the nonbound
portion of cobalt. It has also been suggested that this immediate
decrease in IMA concentration may be attributable to interference
with the IMA measurement by lactate produced during skeletal
muscle work or ischemia. These findings are important for 2 main
reasons: 1) they may cast doubt as to whether IMA changes are
truly representative of cardiac ischemia in patients with chest pain,
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and 2) they raise issues as to the nature of the true stimulus for an
increase in IMA concentrations in patients with chest pain.
There is little doubt, if any, that IMA levels increase during
myocardial ischemia triggered by a primary reduction of blood
flow, as seen in patients during percutaneous coronary intervention
(PCI). Several studies have shown a good correlation among
objective markers of myocardial ischemia, such as lactate levels (4)
isoprostane concentrations (5) and IMA levels, in this setting. We
have therefore suggested that increased IMA levels may result
from increased oxidative stress whether caused by ischemia reper-
fusion injury or other mechanisms linked to primary reductions of
coronary blood flow (5) or muscle damage (6). Indeed, results from
in vitro work from our group support this hypothesis and suggest
that the generation of reactive oxygen species can at least tran-
siently modify the N-terminal region of albumin to yield increased
levels of IMA (7). It is conceivable that the greater the magnitude
of reactive oxygen species formation the higher the elevation of
IMA levels. The production of reactive oxygen species during
balloon occlusion and reperfusion in patients undergoing PCI (8)
and in the acute coronary syndrome setting (9)—where intracoro-
nary thrombosis causes serious reductions in coronary blood
flow—may result in the chemical modification of albumin that
leads to IMA production. Increased oxidative stress production in
these circumstances, together with the lack of antagonistic influ-
ences to IMA measurements that appear to occur during skeletal
muscle exercise (1–3), can explain the consistent finding of
increased IMA levels. Increased oxygen free-radical production,
however, is commonly found in a wide variety of medical condi-
tions other than myocardial ischemia, and this may at least partly
explain both IMA’s baseline variability and relatively low specific-
ity (9).
Further studies are required to understand the mechanisms
leading to increased IMA levels in different clinical conditions of
myocardial ischemia and nonischemic conditions. Moreover, fu-
ture research should be specifically targeted toward identifying the
exact nature of albumin modification and the reasons for the
intriguing findings in relation to exercise, as reported by Sbarouni
et al. (1). Only when these vital mechanisms are elucidated, should
clinical studies be carried out to explore the true potential role of
this marker in clinical practice.
*Debashis Roy, MRCP, MD
Juan Carlos Kaski, MD, DSc, FACC
*Cardiovascular Biology Research Centre
Division of Cardiac and Vascular Sciences
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Reply
We appreciate the interest of Dr. Kalay and colleagues in our study
assessing ischemia-modified albumin (IMA) levels in exercise
stress testing (1). We address their comments:
1. All our patients had angiographically documented coronary
artery disease, the exercise stress test (EST) being part of their
regular follow-up, and the criteria we used for positivity were
rather strict—2-mm horizontal or downsloping ST depression.
In addition, our findings do not differ from Van der Zee et al.
(2), who also observed a significant decrease of IMA plasma
levels at peak exercise and subsequent return to baseline,
without any difference between positive and negative exercise
tests. In that study, single-photon emission computed tomog-
raphy (SPECT) imaging, a more sensitive and specific method
compared to treadmill testing, was used. Therefore, in that
respect, we believe inaccuracies in the EST results (false
positive or negative) cannot be substantiated.
2. Regarding the timing of IMA sampling, percutaneous
coronary intervention (PCI) studies have shown a signifi-
cant increase in IMA plasma levels immediately following
balloon deflation and a return to baseline within 6 to 12 h
(3,4), so we would think that peak exercise is the appropri-
ate time point to assess whether IMA increases in exercise-
induced ischemia.
3. Although we cannot exclude occult peripheral atheroscle-
rosis in our patients, none of the study participants had
clinically significant peripheral vascular disease, by history,
physical examination or clinical presentation. Additionally,
in no patient was the EST limited by skeletal muscle
ischemia, rendering the mechanism of peripheral lactic
acidosis as a cause of decreased exercise IMA levels ex-
tremely unlikely. Furthermore, a very recent report observed
that the rise in IMA plasma levels after PCI parallels that of
transmyocardial lactate, immediately after obstructive bal-
loon inflation (5).
In the letter by Drs. Roy and Kaski regarding our study (1)
they state that IMA decrease at exercise may relate to either
albumin or lactate increase. Albumin plasma levels have been
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